Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year

Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial - The Lancet Neurology

Time is Brain: Management of Acute Ischemic Stroke!

Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era

Safety of Mechanical Thrombectomy and Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke. Results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) Trial, Part I

Tissue-type plasminogen activator - Wikipedia

Full article: Making a case for the right '-ase' in acute ischemic stroke: alteplase, tenecteplase, and reteplase

Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke

IJMS, Free Full-Text

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis - The Lancet

Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review, International Journal of Emergency Medicine

NeuroEMCrit - Time is Brain - Acute Ischemic Stroke Part I: Vascular Syndromes and Thrombolysis

Trends in acute ischemic stroke treatments and mortality in the United States from 2012 to 2018 in: Neurosurgical Focus Volume 51 Issue 1 (2021) Journals

Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial - The Lancet Neurology

Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year